Anti-cancer effect of a quinoxaline derivative GK13 as a transglutaminase 2 inhibitor

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 8, 2013, Pages 1279-1294

  Lee, Seon Hyeong ^b,c   Kim, Nayeon ^a   Kim, Se Jin ^c   Song, Jaewhan ^b   Gong, Young Dae ^a   Kim, Soo Youl ^c  

^a Dongguk University   (South Korea)

^b Yonsei University   (South Korea)

^c National Cancer Center   (South Korea)

Author keywords

Anti cancer drug; Apoptosis; Quinoxaline derivative; Transglutaminase 2

Indexed keywords

[2 (PHENYLETHYNYL) 3 (2 PYRROLIDIN 1 YL)ETHOXY]QUINOXALINE; ANTINEOPLASTIC AGENT; DOXORUBICIN; I KAPPA B ALPHA; PACLITAXEL; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME KINETICS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN POLYMERIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SEPARATION; ENZYME INHIBITORS; FLOW CYTOMETRY; GTP-BINDING PROTEINS; GUINEA PIGS; HUMANS; IMMUNOBLOTTING; QUINOXALINES; TRANSGLUTAMINASES;

EID: 84880925151     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1433-1     Document Type: Article

References (39)

1. Caccamo D, Curro M, Ientile R (2010) Potential of transglutaminase 2 as a therapeutic target. Expert Opin Ther Targets 14(9):989-1003. doi: 10.1517/14728222.2010.510134
2. Choi K, Siegel M, Piper JL, Yuan L, Cho E, Strnad P, Omary B, Rich KM, Khosla C (2005) Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. Chem Biol 12(4):469-475. doi: 10.1016/j.chembiol.2005.02.007
3. Delhase M, Kim SY, Lee H, Naiki-Ito A, Chen Y, Ahn ER, Murata K, Kim SJ, Lautsch N, Kobayashi KS, Shirai T, Karin M, Nakanishi M (2012) TANK-binding kinase 1 (TBK1) controls cell survival through PAI-2/serpinB2 and transglutaminase 2. Proc Natl Acad Sci USA 109(4):E177-E186. doi: 10.1073/pnas.1119296109
4. Folk JE (1980) Transglutaminases. Annu Rev Biochem 49:517-531. doi: 10.1146/annurev.bi.49.070180.002505
5. Folk JE, Park MH, Chung SI, Schrode J, Lester EP, Cooper HL (1980) Polyamines as physiological substrates for transglutaminases. J Biol Chem 255(8):3695-3700
6. Frese-Schaper M, Schardt JA, Sakai T, Carboni GL, Schmid RA, Frese S (2010) Inhibition of tissue transglutaminase sensitizes TRAIL-resistant lung cancer cells through upregulation of death receptor 5. FEBS Lett 584(13):2867-2871. doi: 10.1016/j.febslet.2010.04.072
7. Gong YD, Lee T (2010) Combinatorial syntheses of five-membered ring heterocycles using carbon disulfide and a solid support. J Comb Chem 12(4):393-409. doi: 10.1021/cc100049u
8. Gong YD, Dong MS, Lee SB, Kim N, Bae MS, Kang NS (2011) A novel 3-arylethynyl-substituted pyrido[2,3,-b]pyrazine derivatives and pharmacophore model as Wnt2/beta-catenin pathway inhibitors in non-small-cell lung cancer cell lines. Bioorg Med Chem 19(18):5639-5647. doi: 10.1016/j.bmc.2011.07.028
9. Griffin M, Mongeot A, Collighan R, Saint RE, Jones RA, Coutts IG, Rathbone DL (2008) Synthesis of potent water-soluble tissue transglutaminase inhibitors. Bioorg Med Chem Lett 18(20):5559-5562. doi: 10.1016/j.bmcl.2008.09. 006
10. Gupta R, Srinivasan R, Nijhawan R, Suri V (2010) Tissue transglutaminase 2 as a biomarker of cervical intraepithelial neoplasia (CIN) and its relationship to p16INK4A and nuclear factor kappaB expression. Virchows Arch 456(1):45-51. doi: 10.1007/s00428-009-0860-5
11. Hollingshead MG, Alley MC, Camalier RF, Abbott BJ, Mayo JG, Malspeis L, Grever MR (1995) In vivo cultivation of tumor cells in hollow fibers. Life Sci 57(2):131-141
12. Iismaa SE, Mearns BM, Lorand L, Graham RM (2009) Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders. Physiol Rev 89(3):991-1023. doi: 10.1152/physrev.00044.2008
13. Kim SY (2006) Transglutaminase 2 in inflammation. Front Biosci 11:3026-3035. doi: 10.1007/s00432-009-0681-6
14. Kim SY (2010) A new paradigm for cancer therapeutics development. BMB Rep 43(6):383-388
15. Kim SY (2011) Transglutaminase 2: a new paradigm for NF-kappaB involvement in disease. Adv Enzymol Relat Areas Mol Biol 78:161-195
16. Kim DS, Park SS, Nam BH, Kim IH, Kim SY (2006) Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation. Cancer Res 66(22):10936-10943. doi: 10.1158/0008-5472.CAN-06-1521
17. Kim DS, Park KS, Jeong KC, Lee BI, Lee CH, Kim SY (2009a) Glucosamine is an effective chemo-sensitizer via transglutaminase 2 inhibition. Cancer Lett 273(2):243-249. doi: 10.1016/j.canlet.2008.08.015
18. Kim DS, Park KS, Kim SY (2009b) Silencing of TGase 2 sensitizes breast cancer cells to apoptosis by regulation of survival factors. Front Biosci 14:2514-2521. doi: 10.2741/3394
19. Kim SJ, Kim KH, Ahn ER, Yoo BC, Kim SY (2011) Depletion of cathepsin D by transglutaminase 2 through protein cross-linking promotes cell survival. Amino Acids. doi: 10.1007/s00726-011-1089-6
20. Ku JL, Park JG (2005) Biology of SNU cell lines. Cancer Res Treat 37(1):1-19. doi: 10.4143/crt.2005.37.1.1
21. Lai TS, Liu Y, Tucker T, Daniel KR, Sane DC, Toone E, Burke JR, Strittmatter WJ, Greenberg CS (2008) Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries. Chem Biol 15(9):969-978. doi: 10.1016/j.chembiol.2008.07.015
22. Lee T, Gong YD (2012) Solid-phase parallel synthesis of drug-like artificial 2H-benzopyran libraries. Molecules 17(5):5467-5496. doi: 10.3390/molecules17055467
23. Lee J, Kim YS, Choi DH, Bang MS, Han TR, Joh TH, Kim SY (2004) Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia. J Biol Chem 279(51):53725-53735. doi: 10.1074/jbc.M407627200
24. Lin CY, Tsai PH, Kandaswami CC, Chang GD, Cheng CH, Huang CJ, Lee PP, Hwang JJ, Lee MT (2011) Role of tissue transglutaminase 2 in the acquisition of a mesenchymal-like phenotype in highly invasive A431 tumor cells. Mol Cancer 10:87. doi: 10.1186/1476-4598-10-87
25. Lorand L, Graham RM (2003) Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 4(2):140-156. doi: 10.1038/nrm1014
26. Mann AP, Verma A, Sethi G, Manavathi B, Wang H, Fok JY, Kunnumakkara AB, Kumar R, Aggarwal BB, Mehta K (2006) Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer Res 66(17):8788-8795. doi: 10.1158/0008-5472.CAN-06-1457
27. Molnar Z, Bekesi JG (1972) Cytotoxic effects of D-glucosamine on the ultrastructures of normal and neoplastic tissues in vivo. Cancer Res 32(4):756-765
28. Pardin C, Pelletier JN, Lubell WD, Keillor JW (2008) Cinnamoyl inhibitors of tissue transglutaminase. J Org Chem 73(15):5766-5775. doi: 10.1021/jo8004843
29. Park SS, Kim JM, Kim DS, Kim IH, Kim SY (2006) Transglutaminase 2 mediates polymer formation of I-kappaBalpha through C-terminal glutamine cluster. J Biol Chem 281(46):34965-34972. doi: 10.1074/jbc.M604150200
30. Park KS, Kim DS, Ko C, Lee SJ, Oh SH, Kim SY (2011) TNF-alpha mediated NF-kappaB activation is constantly extended by transglutaminase 2. Front Biosci (Elite Ed) 3:341-354
31. Shao M, Cao L, Shen C, Satpathy M, Chelladurai B, Bigsby RM, Nakshatri H, Matei D (2009) Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase. Cancer Res 69(24):9192-9201. doi: 10.1158/0008-5472.CAN-09-1257
32. Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6(10):813-823. doi: 10.1038/nrc1951
33. Siegel M, Khosla C (2007) Transglutaminase 2 inhibitors and their therapeutic role in disease states. Pharmacol Ther 115(2):232-245. doi: 10.1016/j.pharmthera.2007.05.003
34. Siegel M, Xia J, Khosla C (2007) Structure-based design of alpha-amido aldehyde containing gluten peptide analogues as modulators of HLA-DQ2 and transglutaminase 2. Bioorg Med Chem 15(18):6253-6261. doi: 10.1016/j.bmc.2007. 06.020
35. Sohn J, Kim TI, Yoon YH, Kim JY, Kim SY (2003) Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis. J Clin Invest 111(1):121-128. doi: 10.1172/JCI15937
36. Verhaar R, Jongenelen CA, Gerard M, Baekelandt V, Van Dam AM, Wilhelmus MM, Drukarch B (2011) Blockade of enzyme activity inhibits tissue transglutaminase-mediated transamidation of alpha-synuclein in a cellular model of Parkinson's disease. Neurochem Int 58(7):785-793. doi: 10.1016/j.neuint.2011. 03.004
37. Verma A, Mehta K (2007) Transglutaminase-mediated activation of nuclear transcription factor-kappaB in cancer cells: a new therapeutic opportunity. Curr Cancer Drug Targets 7(6):559-565
38. Yoo H, Ahn ER, Kim SJ, Lee SH, Oh SH, Kim SY (2013) Divergent results induced by different types of septic shock in transglutaminase 2 knockout mice. Amino Acids 44(1):189-197. doi: 10.1007/s00726-012-1412-x
39. Yuan L, Siegel M, Choi K, Khosla C, Miller CR, Jackson EN, Piwnica-Worms D, Rich KM (2007) Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene 26(18):2563-2573. doi: 10.1038/sj.onc.1210048